Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.50
pages 463-483

Immunogenicity of Dendritic-Tumor Fusion Hybrids and Their Utility in Cancer Immunotherapy

Suyu Shu
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Rongxiu Zheng
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Walter T. Lee
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Peter A. Cohen
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

RESUMO

Cancer immunotherapy using fusion hybrid cells generated from dendritic cells (DCs) and tumor cells may be more effective than other DC−based vaccines. DC−tumor fusion potentially confers not only the DCs' antigen-presenting functionality but also a continuing source of endogenous tumor antigens for major-histocompatibility-complex-restricted T−cell sensitization. In animal models, many investigators demonstrated that vaccination with fusion hybrids was protective against tumor challenge and therapeutic, resulting in the regression of established tumors. In clinical trials for patients with a variety of metastatic diseases, fusion hybrid vaccines were well tolerated, but the overall objective response rate was only 10.9%. Careful scrutiny of a large number of publications revealed that, in most cases, no definitive evidence of heterokaryonic fusion cell formation was found. Further corroboration of this conclusion comes from reports that fusion hybrids generated from autologous (syngeneic) and allogeneic DCs displayed equivalent immunological function and therapeutic effects in vitro and in vivo. This puzzling finding suggests that effective fusion immunotherapy depends on tumor antigen scavenging and presentation by antigen-presenting cells (APCs) of host origin and is in violation of the basic tenet of the principle of DC function. We believe that conclusions drawn from reported clinical trials have not properly evaluated the efficacy of the DC−tumor hybrid vaccine, and therefore, they neither confirm nor disclaim the potential benefits that may be derived from this form of immunotherapy.


Articles with similar content:

CD4+ T Cells Orchestrate Both Amplification and Deletion of CD8+T Cells
Critical Reviews™ in Immunology, Vol.18, 1998, issue 6
Enza Piccolella, Loredana Frasca, Cinzia Piazza
Tumor Antigen Presentation by Dendritic Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 4
Nina Dickgreber, Ian F. Hermans, Troels R. Petersen
Role of Dendritic Cells in Host−Mycobacterium Bovis BCG Interactions
Onco Therapeutics, Vol.6, 2015, issue 3-4
Krzysztof Krawczyk, Magdalena Kowalewicz-Kulbat, Wieslawa Rudnicka
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
Tolerance and Cancer: A Critical Issue in Tumor Immunology
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 5-6
Hyam I. Levitsky, Eduardo M. Sotomayor, Ivan Borrello